WALTHAM, Mass. — August 11, 2025 — Leads & Copy — Sionna Therapeutics Inc. (Nasdaq: SION) reported positive Phase 1 data for SION-719 and SION-451, showing the NBD1 stabilizers were generally well tolerated and exceeded pharmacokinetic targets. The company is on track to start a Phase 2a trial of SION-719 in cystic fibrosis patients in the second half of 2025, with topline data expected in mid-2026, and a Phase 1 trial of SION-451 in dual combinations.
Mike Cloonan, President and CEO of Sionna, said the data reinforces confidence in advancing both NBD1 stabilizers. Sionna expects its $337.3 million in cash and equivalents to fund operations into 2028.
In June, Sionna presented preclinical data demonstrating its NBD1 stabilizers, in dual combinations with complementary modulators, enable full correction of F508del-CFTR in CF models at the European Cystic Fibrosis Society’s (ECFS) 48th Annual Conference.
Research and development expenses were $15.4 million for the second quarter of 2025, compared to $8.2 million for the second quarter of 2024. The net loss was $18.1 million for the second quarter of 2025, compared to a net loss of $8.6 million for the second quarter of 2024.
Contact:
Adam Daley
CG Life
212.253.8881
adaley@cglife.com
Juliet Labadorf
ir@sionnatx.com
Source: Sionna Therapeutics, Inc.
